Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain
暂无分享,去创建一个
K. Joo | R. Nam | Y. Chung | Min Kyu Kim | C. Cha | K. Lee | Byung Lan Lee
[1] P. Gressens,et al. VIP and PACAP induce selective neuronal differentiation of mouse embryonic stem cells , 2004, The European journal of neuroscience.
[2] N. Mizuno,et al. Substance P-, vasoactive intestinal polypeptide-, and cholecystokinin-like immunoreactive fiber projections from the superior colliculus to the dorsal lateral geniculate nucleus in the rat , 2004, Experimental Brain Research.
[3] Sang-Hun Lee,et al. Vasoactive intestinal peptide selectively depolarizes thalamic relay neurons and attenuates intrathalamic rhythmic activity. , 2003, Journal of neurophysiology.
[4] H. Vaudry,et al. Pituitary adenylate cyclase‐activating polypeptide prevents C2‐ceramide‐induced apoptosis of cerebellar granule cells , 2003, Journal of neuroscience research.
[5] D. Prince,et al. Vasoactive Intestinal Polypeptide and Pituitary Adenylate Cyclase-Activating Polypeptide Activate Hyperpolarization-Activated Cationic Current and Depolarize Thalamocortical Neurons In Vitro , 2003, The Journal of Neuroscience.
[6] H. Vaudry,et al. Pituitary adenylate cyclase‐activating polypeptide (PACAP) stimulates endozepine release from cultured rat astrocytes via a PKA‐dependent mechanism , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[7] H. Vaudry,et al. Pituitary Adenylate Cyclase-Activating Polypeptide Prevents C 2-Ceramide-Induced Apoptosis of Cerebellar Granule Cells , 2003 .
[8] J. Hannibal. Pituitary adenylate cyclase‐activating peptide in the rat central nervous system: An immunohistochemical and in situ hybridization study , 2002, The Journal of comparative neurology.
[9] Jie Liu,et al. Local administration of vasoactive intestinal peptide after nerve transection accelerates early myelination and growth of regenerating axons , 2002, Journal of the peripheral nervous system : JPNS.
[10] E. Maywood,et al. The VPAC2 Receptor Is Essential for Circadian Function in the Mouse Suprachiasmatic Nuclei , 2002, Cell.
[11] H. Vaudry,et al. PACAP protects cerebellar granule neurons against oxidative stress‐induced apoptosis , 2002, The European journal of neuroscience.
[12] H. Vaudry,et al. Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[13] M. Kim,et al. Age-related changes in the distribution of nitrotyrosine in the cerebral cortex and hippocampus of rats , 2002, Brain Research.
[14] F. Jirik,et al. Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. , 2001, Molecular endocrinology.
[15] M. Brunelli,et al. Differential effects of PACAP-38 on synaptic responses in rat hippocampal CA1 region. , 2001, Learning & memory.
[16] F. Mcmorris,et al. Agonists calcitonin, corticotropin‐releasing hormone, and vasoactive intestinal peptide, but not prostaglandins or β‐adrenergic agonists, elevate cyclic adenosine monophosphate levels in oligodendroglial cells , 2001, Journal of neuroscience research.
[17] F. Jamen,et al. Dissociation between Light-Induced Phase Shift of the Circadian Rhythm and Clock Gene Expression in Mice Lacking the Pituitary Adenylate Cyclase Activating Polypeptide Type 1 Receptor , 2001, The Journal of Neuroscience.
[18] P. Zhao,et al. Pituitary Adenylyl Cyclase-Activating Polypeptide Stimulates DNA Synthesis But Delays Maturation of Oligodendrocyte Progenitors , 2001, The Journal of Neuroscience.
[19] D. Cutler,et al. Vasoactive intestinal polypeptide (VIP) phase‐shifts the rat suprachiasmatic nucleus clock in vitro , 2001, The European journal of neuroscience.
[20] F. Holsboer,et al. Mild deficits in mice lacking pituitary adenylate cyclase-activating polypeptide receptor type 1 (PAC1) performing on memory tasks. , 2000, Brain research. Molecular brain research.
[21] N. Sherwood,et al. THE ORIGIN AND FUNCTION OF THE PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP)/GLUCAGON SUPERFAMILY , 2000 .
[22] S. Said. The Viktor Mutt Memorial Lecture Protection by VIP and Related Peptides Against Cell Death and Tissue Injury , 2000, Annals of the New York Academy of Sciences.
[23] A Fournier,et al. Comparative distribution of pituitary adenylate cyclase‐activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development , 2000, The Journal of comparative neurology.
[24] M. Sofroniew,et al. Pituitary adenylate cyclase‐activating polypeptide promotes the survival of basal forebrain cholinergic neurons in vitro and in vivo: comparison with effects of nerve growth factor , 2000, The European journal of neuroscience.
[25] H. Vaudry,et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. , 2000, Pharmacological reviews.
[26] J. Bockaert,et al. PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. , 2000, The Journal of clinical investigation.
[27] E. Melamed,et al. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease 1 This manuscript is based on a poster presented at the Brain Research Interactive Symposium on “Neuropeptides at the Millennium”, Miami, October 1999. 1 , 2000, Brain Research.
[28] I. Gozes,et al. Vasoactive Intestinal Peptide: Link between Electrical Activity and Glia‐mediated Neurotrophism , 1999, Annals of the New York Academy of Sciences.
[29] J. Hannibal,et al. Pituitary adenylyl cyclase-activating peptide: a pivotal modulator of glutamatergic regulation of the suprachiasmatic circadian clock. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[30] J. Burgunder,et al. Thalamic reticular nucleus parcellation delineated by VIP and TRH gene expression in the rat , 1999, Journal of Chemical Neuroanatomy.
[31] H. Vaudry,et al. Neurotrophic activity of pituitary adenylate cyclase-activating polypeptide on rat cerebellar cortex during development. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[32] S. Cavallaro,et al. Functional and molecular diversity of PACAP/VIP receptors in cortical neurons and type I astrocytes , 1999, The European journal of neuroscience.
[33] G. Sachs,et al. The Pituitary Adenylate Cyclase Activating Polypeptide Type 1 Receptor (PAC1‐R) Is Expressed on Gastric ECL Cells: Evidence by Immunocytochemistry and RT‐PCR , 1998, Annals of the New York Academy of Sciences.
[34] K. Dickman,et al. Glutamate Toxicity in the Lung and Neuronal Cells: Prevention or Attenuation by VIP and PACAP , 1998, Annals of the New York Academy of Sciences.
[35] H. Arima,et al. Anorectic Effect of Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) in Rats: Lack of Evidence for Involvement of Hypothalamic Neuropeptide Gene Expression , 1998, Journal of neuroendocrinology.
[36] H. Vaudry,et al. Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos gene expression and cell survival in rat cerebellar granule neurons through activation of the protein kinase A pathway , 1998, Neuroscience.
[37] S. Schiffmann,et al. Autoradiographic Visualization of the Receptor Subclasses for Vasoactive Intestinal Polypeptide (VIP) in Rat Brain , 1997, Peptides.
[38] I. Gozes,et al. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. , 1997, Journal of neurobiology.
[39] S. Shioda,et al. Localization and gene expression of the receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain , 1997, Neuroscience Research.
[40] K. Matsumoto,et al. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells. , 1997, Endocrinology.
[41] H. Vaudry,et al. Pituitary adenylate cyclase-activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts , 1997, Neuroscience.
[42] Tony Wu,et al. Vasoactive intestinal polypeptide enhances the GABAergic synaptic transmission in cultured hippocampal neurons , 1997, Brain Research.
[43] R. V. Sharma,et al. Molecular Cloning of a Novel Variant of the Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) Receptor That Stimulates Calcium Influx by Activation of L-type Calcium Channels* , 1996, The Journal of Biological Chemistry.
[44] R. Shigemoto,et al. Distribution of the mRNA for a pituitary adenylate cyclase‐activating polypeptide receptor in the rat brain: An in situ hybridization study , 1996, The Journal of comparative neurology.
[45] S. Rawlings,et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. , 1996, Endocrine reviews.
[46] I. Gozes,et al. Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[47] J. Fischer,et al. Anorectic and neurochemical effects of pituitary adenylate cyclase activating polypeptide in rats , 1995, Peptides.
[48] B. Rusak,et al. Neuropeptides phase shift the mammalian circadian pacemaker , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[49] A. Harmar,et al. The distribution of vasoactive intestinal peptide2 receptor messenger RNA in the rat brain and pituitary gland as assessed by in situ hybridization , 1995, Neuroscience.
[50] T. Bonner,et al. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. , 1994, Endocrinology.
[51] J. Curlewis,et al. Effects of Pituitary Adenylate Cyclase‐Activating Polypeptide (PACAP) and Vasoactive Intestinal Polypeptide (VIP) on Prolactin, Luteinizing Hormone and Growth Hormone Secretion in the Ewe , 1994, Journal of neuroendocrinology.
[52] G. Fink,et al. Pituitary adenylate cyclase-activating peptide-38 (PACAP)-38 is released into hypophysial portal blood in the normal male and female rat. , 1994, The Journal of endocrinology.
[53] T. Harmar,et al. Multiple receptors for PACAP and VIP. , 1994, Trends in pharmacological sciences.
[54] T. Koike,et al. Vasoactive intestinal peptide suppresses neuronal cell death induced by nerve growth factor deprivation in rat sympathetic ganglion cells in vitro , 1994, Neuropeptides.
[55] G. Fink,et al. The VIP2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide , 1993, FEBS letters.
[56] Laurent Journot,et al. Differential signal transduction by five splice variants of the PACAP receptor , 1993, Nature.
[57] R. Shigemoto,et al. Molecular cloning and tissue distribution of a receptor for pituitary adenylate cyclase-activating polypeptide , 1993, Neuron.
[58] S. Wank,et al. Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[59] N. Barzilai,et al. 38‐Amino acid form of pituitary adenylate cyclase activating peptide induces process outgrowth in human neuroblastoma cells , 1993, Journal of neuroscience research.
[60] E. Goetzl,et al. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. , 1993, Biochemical and biophysical research communications.
[61] Larry W. Swanson,et al. Brain Maps: Structure of the Rat Brain , 1992 .
[62] R. Shigemoto,et al. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide , 1992, Neuron.
[63] B. Gähwiler,et al. Vasoactive intestinal polypeptide modulates neuronal excitability in hippocampal slices of the rat , 1992, Neuroscience.
[64] A. Arimura,et al. Comparative distribution of immunoreactive pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in rat forebrain. , 1991, Neuroendocrinology.
[65] S. Lipton,et al. VIP-mediated increase in cAMP prevents tetrodotoxin-induced retinal ganglion cell death in vitro , 1990, Neuron.
[66] M. Culler,et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. , 1989, Biochemical and biophysical research communications.
[67] M. Tohyama,et al. The organization of the rat lateral geniculate body by immunohistochemical analysis of neuroactive substances , 1989, Brain Research.
[68] Karen L. Elkins,et al. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide , 1988, Nature.
[69] W. Rostène,et al. Characterization and autoradiographic distribution of vasoactive intestinal peptide binding sites in the rat central nervous system , 1986, Brain Research.
[70] N. Tamaki,et al. Effect of vasoactive intestinal polypeptide on growth hormone secretion in perifused acromegalic pituitary adenoma tissues. , 1982, The Journal of clinical endocrinology and metabolism.
[71] J. Fahrenkrug,et al. VIP STIMULATES PROLACTIN RELEASE IN WOMEN , 1981, The Lancet.
[72] O. K. Langley,et al. Double labeling immunohistochemical technique provides evidence of the specificity of glial cell markers. , 1979, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[73] S. Said,et al. Vasoactive intestinal polypeptide: release into hypophyseal portal blood. , 1979, Life sciences.
[74] E. C. Christian,et al. Letter: Primary liver-cell carcinoma in Accra. , 1976, Lancet.
[75] V. Mutt,et al. Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.